Fusion Pharmaceuticals Inc (FUSN)
21.42
0.00 (0.00%)
USD |
NASDAQ |
May 07, 15:22
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.815B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 410.0% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 636.25 |
| Price to Book Value | 8.156 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company’s focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |
| URL | https://www.fusionpharma.com |
| Investor Relations URL | https://ir.fusionpharma.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 20, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company’s focus is on the development of next-generation radiopharmaceuticals as precision medicines for hard-to-treat cancers. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |
| URL | https://www.fusionpharma.com |
| Investor Relations URL | https://ir.fusionpharma.com/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 10, 2024 (est.) |
| Last Earnings Release | Mar. 20, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |